Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Accounts Payables (2021 - 2025)

Historic Accounts Payables for Coeptis Therapeutics Holdings (COEP) over the last 5 years, with Q3 2025 value amounting to $783103.0.

  • Coeptis Therapeutics Holdings' Accounts Payables fell 3095.81% to $783103.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $783103.0, marking a year-over-year decrease of 3095.81%. This contributed to the annual value of $1.3 million for FY2024, which is 1056.11% down from last year.
  • As of Q3 2025, Coeptis Therapeutics Holdings' Accounts Payables stood at $783103.0, which was down 3095.81% from $1.0 million recorded in Q2 2025.
  • Coeptis Therapeutics Holdings' 5-year Accounts Payables high stood at $1.4 million for Q4 2023, and its period low was $31816.0 during Q1 2021.
  • In the last 5 years, Coeptis Therapeutics Holdings' Accounts Payables had a median value of $632554.0 in 2023 and averaged $683380.4.
  • As far as peak fluctuations go, Coeptis Therapeutics Holdings' Accounts Payables skyrocketed by 291337.18% in 2022, and later crashed by 6557.95% in 2023.
  • Coeptis Therapeutics Holdings' Accounts Payables (Quarter) stood at $134092.0 in 2021, then dropped by 26.15% to $99021.0 in 2022, then skyrocketed by 1333.74% to $1.4 million in 2023, then decreased by 10.56% to $1.3 million in 2024, then plummeted by 38.33% to $783103.0 in 2025.
  • Its last three reported values are $783103.0 in Q3 2025, $1.0 million for Q2 2025, and $1.1 million during Q1 2025.